Johnson & Johnson (JNJ) Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
49 articles, transcripts, and reports
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (NYSE: JNJ) Q4 2025 Earnings Call dated Jan. 21, 2026 Corporate Participants: Darren Snellgrove — Vice President of Investor Relations Joaquin Duato…
Johnson & Johnson (NYSE: JNJ) Q2 2025 Earnings Call dated Jul. 16, 2025 Corporate Participants: Darren Snellgrove — Vice President, Investor Relations Joaquin Duato —…
Johnson & Johnson (NYSE: JNJ) Q3 2025 Earnings Call dated Oct. 14, 2025 Corporate Participants: Darren Snellgrove — Vice President of Investor Relations Joaquin Duato…
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today. Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was…
Earnings Preview Overview Johnson & Johnson approaches earnings as a focused healthcare company following the consumer health separation. Results will...
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2025 earnings results today. Reported sales increased 5.8% year-over-year to $23.7 billion. Operational sales growth was…
Johnson & Johnson (NYSE: JNJ) is set to publish its December-quarter report on January 22, amid expectations for mixed results. The company, which has faced…
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today. Reported sales increased 5.2% year-over-year to $22.5 billion. GAAP earnings decreased 37.5% to…
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2024 earnings results today. Reported sales increased 4.3% year-over-year to $22.4 billion. Operational sales growth was 6.6%.…